Trial Profile
Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy - A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes (EORTC Protocol 10041 – BIG 3-04)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary) ; Anthracyclines; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Methotrexate
- Indications Carcinoma; Ductal carcinoma; Early breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MINDACT; MINDACT
- 16 Nov 2022 Status changed from active, no longer recruiting to completed.
- 05 Sep 2022 The trial has been completed in Spain, according to European Clinical Trials Database record.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology